Chronosdx
Entrepreneur First '22London, GB · Founded 2022 · 1 known investors
ChronosDx is developing a biosensor chip based on organic semiconductors that detects biomarkers in real time. The device is designed to be small enough for implantation and to return results without sending samples to a laboratory. Its intended applications are point-of-care testing and earlier detection of disease.
Also known as Chronos DX · ChronosDx · CHRONOSDX LTD
Founders & leadership
Chronosdx was founded in 2022 by Ella Mi and James Tyrrell.
Investors · 1
Company profile
researched Aug 2026ChronosDx (registered as CHRONOSDX LTD, and listed by investor SOSV as "Chronos DX") is a London-based biotechnology company developing a bioassay platform technology. According to SOSV, the platform is aimed at two use cases: drug assays performed on in vitro cell models, and non-invasive diagnostics performed on body fluids. The platform is described as enabling highly sensitive, precision quantification across a broad range of biomarker classes, including proteins, metabolites, microRNAs, cell-free DNA and exosomes.
The company positions the technology as multi-omic, with stated capability for in-line and in vivo continuous monitoring of biomarkers. SOSV states the platform draws on four years of prior research into single-molecule detection and dynamic concentration ranges, and combines low-cost fabrication with scalable production. Companies House records classify the business under SIC code 72110, research and experimental development on biotechnology, consistent with an R&D-stage company.
The company's stated initial commercial focus is in vitro cell-based assays for cancer drug development and liquid biopsy for early cancer detection. Publicly available sources contain no product revenue, customer, headcount or funding-amount disclosures.
Founding story
The company was co-founded by Ella Mi and James Tyrrell, both of whom are listed by SOSV as co-founders and were appointed directors of CHRONOSDX LTD at its incorporation on 22 June 2022. SOSV states the platform builds on four years of prior research into single-molecule detection and dynamic concentration ranges. No further account of the founding is given in the sources.
Business model
ChronosDx is a pre-seed deep-tech company developing a proprietary bioassay/biosensor platform rather than a service offering. Per SOSV, the approach combines low-cost fabrication with scalable production, indicating an intent to commercialise assay/sensor products; the sources do not describe pricing, contracting or distribution arrangements.
Not disclosed in the available sources.
Traction
Publicly documented traction is limited to selection into SOSV's HAX 2022 accelerator cohort and inclusion in the SOSV portfolio at pre-seed stage, plus continued active registration at Companies House with accounts filed up to 30 June 2025. No revenue, customer, pilot or funding-amount figures appear in the sources.
Latest developments
The most recent verifiable public records are Companies House filings showing the company remains active, with last accounts made up to 30 June 2025 and a confirmation statement last dated 3 July 2026. The only documented leadership change is the resignation of co-founder James Tyrrell as a director on 15 July 2023. No funding announcements, product launches or partnerships appear in the available sources.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
ChronosDx is an early-stage (pre-seed, per SOSV's portfolio listing) UK biotechnology company within SOSV's Human Health, Healthcare, Therapeutics and Female Founders portfolio categories, drawn from the HAX 2022 cohort. The sources provide no market share, competitive ranking or comparative data.
SOSV attributes the platform's differentiation to sensitivity and breadth: precision quantification across multiple biomarker classes (proteins, metabolites, microRNAs, cell-free DNA, exosomes) within a single multi-omic platform, insights from four years of research into single-molecule detection and dynamic concentration ranges, low-cost and scalable fabrication, and the capability for in-line and in vivo continuous biomarker monitoring. The sources do not provide independent benchmarking against comparable platforms.
Technology
SOSV describes a bioassay platform technology capable of highly sensitive, precision quantification of a wide range of biomarkers, including proteins, metabolites, microRNAs, cell-free DNA and exosomes, on both in vitro cell models and body fluids. The platform is said to combine low-cost fabrication and scalable production with research insights, developed over four years, into single-molecule detection and dynamic concentration ranges, in a multi-omic architecture that supports in-line and in vivo continuous biomarker monitoring. The public sources do not detail the underlying device physics, materials or validation data.
Go-to-market
SOSV states the first target market is in vitro cell-based assays for cancer drug development, followed by liquid biopsy for early cancer detection, described as high-value areas where the technology is said to have particular advantages. No named customers, partners, pilots or sales channels appear in the sources.
Per SOSV, the initial customers are in cancer drug development, via in vitro cell-based assays, and in early cancer detection, via liquid biopsy on body fluids. The platform's non-invasive diagnostic and continuous-monitoring capabilities point to clinical and research diagnostics users, though no specific customers are named.
Geography
London, United Kingdom. The Companies House registered office is 128 City Road, London EC1V 2NX, and SOSV lists the company's location as London, United Kingdom. No other sites or markets are documented in the sources.
History
The UK entity CHRONOSDX LTD (company number 14189432) was incorporated on 22 June 2022 with a registered office at 128 City Road, London EC1V 2NX, and is registered under SIC code 72110, research and experimental development on biotechnology. Ella Mi and James Tyrrell were both appointed directors at incorporation; Tyrrell resigned as a director on 15 July 2023, leaving Mi as the sole active director. The company participated in SOSV's HAX 2022 cohort and is listed in the SOSV portfolio at pre-seed stage. As of the most recent Companies House record, the company status is Active, with last accounts made up to 30 June 2025 and the next confirmation statement due in July 2027.
Risks & controversies
No controversies are documented in the sources. Notable risk-relevant facts: the company is at pre-seed stage with no disclosed funding amounts, revenue or customers in public sources; co-founder and CTO James Tyrrell resigned as a company director on 15 July 2023, leaving one active director; and the stated applications (cancer drug development assays, liquid biopsy, in vivo monitoring) are in regulated, capital-intensive diagnostics markets. Public descriptions of the technology also differ in emphasis between an implantable organic-semiconductor biosensor chip and a broader bioassay platform for in vitro cell models and body fluids.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsCompanies House records show James Tyrrell, appointed director on 22 June 2022, resigned on 15 July 2023. Ella Mi remains an active director.
CHRONOSDX LTD was incorporated as a private limited company (company number 14189432) on 22 June 2022, with a registered office at 128 City Road, London EC1V 2NX and SIC code 72110 (research and experimental development on biotechnology).
SOSV lists Chronos DX as a portfolio company in the HAX 2022 cohort, at pre-seed stage, in the Healthcare/Human Health categories.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 7
primary sources listed
- Chronos DX - SOSVsosv.com · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Chronosdx do?
- London pre-seed biotech developing a highly sensitive bioassay platform for cell-based drug assays and liquid-biopsy cancer detection.
- Who founded Chronosdx?
- Chronosdx was founded by Ella Mi, James Tyrrell in 2022.
- Who are Chronosdx's investors?
- Chronosdx's investors include Entrepreneur First.
- Where is Chronosdx headquartered?
- Chronosdx is headquartered in London, GB.